Comparison of outcomes between known and unknown aetiology of pancreatitis in SARS-CoV-2-positive patients
| Outcome | Known aetiology | Unknown aetiology | OR (95% CI)† | P value | ||
| N* | n (%) | N | n (%) | |||
| ICU admission | 111 | 20 (18.0%) | 37 | 9 (7.3%) | 1.49 (0.59 to 3.79) | 0.40 |
| 30-day mortality | 103 | 12 (11.7%) | 35 | 6 (17.1%) | 1.57 (0.54 to 4.56) | 0.41 |
| Length of stay‡ | 100 | 8 (5, 16) | 35 | 12 (5, 21) | 1.26 (0.91 to 1.73) | 0.16 |
| Pancreatic necrosis | 105 | 22 (21.0%) | 34 | 9 (26.5%) | 1.36 (0.55 to 3.32) | 0.50 |
| Acute pancreatic fluid collections | 107 | 43 (40.2%) | 34 | 17 (50.0%) | 1.54 (0.68 to 3.50) | 0.30 |
| Pseudoaneurysm | 107 | 1 (0.9%) | 34 | 0 (0.0%) | – | § |
| Pancreato-pleural fistula | 106 | 0 (0.0%) | 33 | 0 (0.0%) | – | § |
| Enteric fistula | 107 | 2 (1.9%) | 32 | 0 (0.0%) | – | § |
| Pancreatic ascites | 107 | 14 (13.1%) | 34 | 6 (17.7%) | 1.77 (0.50 to 6.22) | 0.37 |
| Portal vein thrombus | 105 | 1 (1.0%) | 34 | 2 (5.9%) | 6.50 (0.57 to 74.0) | 0.13 |
| Any local complication¶ | 105 | 47 (44.8%) | 34 | 18 (52.9%) | 1.41 (0.63 to 3.20) | 0.41 |
| Persistent organ failure | 111 | 29 (26.1%) | 36 | 15 (41.7%) | 2.09 (0.88 to 4.95) | 0.09 |
*Indicates the number of patients included in the analysis.
†ORs expressed as odds in unknown aetiology group relative to the odds in known aetiology group.
‡Summary statistics are: median (p75–p25). Group differences reported as: ratio (95% CI).
§Insufficient occurrences to enable a formal group comparison.
¶Defined as any of: acute pancreatic fluid collection, pseudoaneurysm, pancreatic pleural fistula, enteric fistula, pancreatic ascites or portal vein thrombus.